If you have an immunosuppressive disease or take blood thinners, your response to advanced skin cancer treatment may differ significantly from others. A new study of 273 patients with advanced cutaneous squamous cell carcinoma (CSCC), a serious form of skin cancer, found that underlying health conditions and everyday medications dramatically influence how well immunotherapy works. What Health Conditions Affect Skin Cancer Treatment Outcomes? Researchers from the German Dermatologic Cooperative Oncology Group analyzed data from patients with unresectable or metastatic CSCC (meaning the cancer had spread or couldn't be surgically removed) who received immune checkpoint inhibitors (ICIs), a type of immunotherapy that helps the body's immune system fight cancer. The study, published in the Journal of the European Academy of Dermatology and Venereology, examined how comorbidities (other existing health conditions) and medications affected survival rates. The most striking finding involved patients with immunosuppressive diseases, which weaken the immune system. These patients had dramatically worse outcomes. Their median overall survival was just 16.6 months compared to 34.1 months for patients without immunosuppressive diseases, roughly half the survival time. Progression-free survival, the time before cancer started spreading again, was also cut short at 5.5 months versus 24.4 months. The study included 273 patients, of whom 253 received immunotherapy as a first-line treatment. The median age at diagnosis was 80 years, and 84.2% were men. Among this group, several common health conditions were prevalent: - Cardiovascular Comorbidities: Present in 61.6% of patients, making it the most frequent underlying condition in the study population - Endocrine and Metabolic Disorders: Found in 42% of patients, including conditions like diabetes that affect hormone and blood sugar regulation - Other Cancers: A history of other neoplasms (cancers) was documented in 30.2% of the study participants How Do Medications Change Treatment Effectiveness? Beyond underlying diseases, the medications patients were already taking showed surprising effects on immunotherapy success. Anticoagulants, commonly known as blood thinners and used to prevent blood clots, were associated with significantly better outcomes. Patients taking anticoagulants had a median progression-free survival of 49.3 months compared to just 17.4 months for those not taking them. This nearly threefold improvement was statistically significant and held up even after researchers adjusted for other factors. Conversely, hydrochlorothiazide, a common blood pressure medication, was linked to reduced progression-free survival. Patients taking this diuretic had shorter times before their cancer began progressing again. However, this medication did not affect overall survival rates. Other medications showed no significant impact. Antibiotic use and metformin, a diabetes medication, did not meaningfully change how well immunotherapy worked or how long patients survived. Steps to Optimizing Your Skin Cancer Treatment Plan - Discuss All Medications: Before starting immunotherapy for skin cancer, review every medication you take with your dermatologist or oncologist, including blood thinners, blood pressure drugs, and diabetes medications, as they may influence treatment effectiveness - Report Immunosuppressive Conditions: Inform your healthcare team about any conditions that weaken your immune system, such as HIV, organ transplant status, or autoimmune diseases, since these significantly affect survival outcomes and may require adjusted treatment strategies - Undergo Risk Stratification: Ask your doctor to perform individualized risk assessment based on your specific health profile rather than assuming standard treatment protocols will work equally well for everyone The research underscores an important shift in cancer care. Rather than applying the same treatment approach to all patients, doctors are increasingly recognizing that individual health profiles matter enormously. As the study authors noted, "This study underscores the relevance of host-related factors on the outcome of immunotherapy in patients with advanced CSCC. It highlights the need for individualized risk stratification and suggests that widely used medications, such as anticoagulants, may influence the effectiveness of ICI". The study analyzed data from the ADOReg skin cancer registry between 2016 and 2024, making it one of the largest real-world analyses of how comorbidities and medications affect advanced skin cancer treatment. Of the 273 patients included, 92.7% received immunotherapy as a first-line treatment, 8.8% as second-line, and 4.4% as third-line therapy. While the study has limitations, including its retrospective design and lack of detailed information about medication adherence over time, the findings have immediate clinical relevance. If you have been diagnosed with advanced cutaneous squamous cell carcinoma or are at risk for this type of skin cancer, these results suggest that a personalized approach to treatment planning, accounting for your specific medications and health conditions, may significantly improve your chances of better outcomes. Discuss these findings with your dermatology or oncology team to ensure your treatment plan accounts for your individual health profile.
